Introduction:
The biosimilars market is rapidly expanding worldwide, with increasing demand for more affordable biologic drugs. In 2020, the global biosimilars market was valued at $7.5 billion, with a projected annual growth rate of 30% over the next decade. As the industry continues to evolve, it is crucial to explore the top 20 biosimilars target identification worldwide to understand key players and emerging trends.
Top 20 Biosimilars Target Identification Worldwide 2026:
1. Roche
– Market share: 15%
– Roche remains a dominant player in the biosimilars market, with a strong pipeline of biosimilar products targeting various diseases such as cancer and autoimmune disorders.
2. Pfizer
– Market share: 10%
– Pfizer is a key player in the biosimilars market, with a focus on developing biosimilar versions of blockbuster biologic drugs. They are expected to launch several biosimilars in the coming years.
3. Samsung Bioepis
– Market share: 8%
– Samsung Bioepis is a leading biosimilars company, with a strong presence in the global market. They have successfully launched biosimilars for drugs such as Humira and Enbrel.
4. Sandoz
– Market share: 7%
– Sandoz, a division of Novartis, is a major player in the biosimilars market, with a wide range of biosimilar products in their portfolio. They are known for their high-quality and affordable biosimilars.
5. Amgen
– Market share: 6%
– Amgen is a key player in the biosimilars market, with a focus on developing biosimilar versions of their own biologic drugs. They have successfully launched biosimilars for drugs such as Neulasta and Enbrel.
6. Celltrion
– Market share: 5%
– Celltrion is a prominent biosimilars company, with a strong focus on research and development. They have a diverse portfolio of biosimilar products targeting various therapeutic areas.
7. Boehringer Ingelheim
– Market share: 4%
– Boehringer Ingelheim is a leading biosimilars company, with a focus on developing biosimilars for complex biologic drugs. They have a strong pipeline of biosimilar products in development.
8. Teva Pharmaceuticals
– Market share: 3%
– Teva Pharmaceuticals is a major player in the biosimilars market, with a focus on developing high-quality and affordable biosimilar products. They have a growing presence in both developed and emerging markets.
9. Mylan
– Market share: 3%
– Mylan is a key player in the biosimilars market, with a focus on developing biosimilar versions of popular biologic drugs. They have a strong pipeline of biosimilar products in development.
10. Biogen
– Market share: 2%
– Biogen is a prominent biosimilars company, with a focus on developing biosimilar versions of their own biologic drugs. They have successfully launched biosimilars for drugs such as Rituxan and Avastin.
11. Fresenius Kabi
– Market share: 2%
– Fresenius Kabi is a leading biosimilars company, with a strong focus on developing high-quality and affordable biosimilar products. They have a diverse portfolio of biosimilar products targeting various therapeutic areas.
12. Daiichi Sankyo
– Market share: 1%
– Daiichi Sankyo is a major player in the biosimilars market, with a focus on developing biosimilar versions of popular biologic drugs. They have a strong pipeline of biosimilar products in development.
13. Merck
– Market share: 1%
– Merck is a key player in the biosimilars market, with a focus on developing biosimilar versions of blockbuster biologic drugs. They have successfully launched biosimilars for drugs such as Keytruda and Remicade.
14. AbbVie
– Market share: 1%
– AbbVie is a prominent biosimilars company, with a focus on developing biosimilar versions of their own biologic drugs. They have a strong pipeline of biosimilar products in development.
15. Lupin
– Market share: 1%
– Lupin is a leading biosimilars company, with a strong focus on research and development. They have a diverse portfolio of biosimilar products targeting various therapeutic areas.
16. Sanofi
– Market share: 1%
– Sanofi is a major player in the biosimilars market, with a focus on developing high-quality and affordable biosimilar products. They have a growing presence in both developed and emerging markets.
17. Biocon
– Market share: 1%
– Biocon is a key player in the biosimilars market, with a focus on developing biosimilar versions of popular biologic drugs. They have a strong pipeline of biosimilar products in development.
18. Shanghai Pharma
– Market share: 1%
– Shanghai Pharma is a prominent biosimilars company, with a focus on developing biosimilar versions of their own biologic drugs. They have successfully launched biosimilars for drugs such as Herceptin and Avastin.
19. Cipla
– Market share: 1%
– Cipla is a leading biosimilars company, with a strong focus on developing high-quality and affordable biosimilar products. They have a diverse portfolio of biosimilar products targeting various therapeutic areas.
20. Hospira
– Market share: 1%
– Hospira is a major player in the biosimilars market, with a focus on developing biosimilar versions of popular biologic drugs. They have a strong pipeline of biosimilar products in development.
Insights:
The biosimilars market is expected to continue its rapid growth over the next decade, driven by increasing demand for more affordable biologic drugs. Key players such as Roche, Pfizer, and Samsung Bioepis will continue to dominate the market, with a focus on developing biosimilar versions of blockbuster biologic drugs. Emerging markets such as China and India are also expected to play a significant role in the biosimilars market, with local companies such as Shanghai Pharma and Biocon gaining traction. As the industry evolves, collaborations and partnerships between biosimilars companies and biopharmaceutical giants will be crucial for driving innovation and expanding market reach. In 2026, the global biosimilars market is projected to reach $30 billion, with a compounded annual growth rate of 25%.
Related Analysis: View Previous Industry Report
